CN1276728A - 对金黄色葡萄球菌的治疗 - Google Patents
对金黄色葡萄球菌的治疗 Download PDFInfo
- Publication number
- CN1276728A CN1276728A CN98810295A CN98810295A CN1276728A CN 1276728 A CN1276728 A CN 1276728A CN 98810295 A CN98810295 A CN 98810295A CN 98810295 A CN98810295 A CN 98810295A CN 1276728 A CN1276728 A CN 1276728A
- Authority
- CN
- China
- Prior art keywords
- staphylococcus aureus
- sensitivity
- glycopeptide
- van
- resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及一种治疗由降低了糖肽敏感性的金黄色葡萄球菌引起的传染病的方法。本发明优选用于对甲氧苯青霉素有抗性的金黄色葡萄球菌诸如Mu50菌株上。
Description
历史上传染病夺走了大量人的生命。本世纪，许多这些传染病已通过抗菌药物受到了控制。但是，细菌能够突变并在许多情况下通过突变而产生对迄今为止可有效控制其的抗菌剂的抗性。
例如，糖肽万古霉素用于控制由于革兰氏阳性细菌(包括肠球菌属和葡萄球菌属)引起的感染已有近四十年。最近另一种糖肽游壁菌素也已用来控制革兰氏阳性细菌。但是，最近，已经出现了对这些糖肽不那么敏感的细菌菌株。这些菌株可能只是降低了敏感性，或者在某些情况下它们完全有抗药性以及所述糖肽没有效果。
因此，需要有新的治疗方法来治疗由于降低了敏感性或有抗性菌株的感染。
本发明涉及降低了对糖肽敏感性的金黄色葡萄球菌菌株的控制方法。这些方法使用了化合物NDISACC-(4-(4-氯苯基)苄基)A82846B或其药物上可接受的盐。
在本发明中，NDISACC-(4-(4-氯苯基)苄基)A82846B或其药物上可接受的盐被用于治疗罹患降低了糖肽敏感性的金黄色葡萄球菌菌株的细菌感染的宿主动物。NDISACC-(4-(4-氯苯基)苄基)A82846B和其盐被描述于通过引用并入本文的公开的EPO0667353中。参见实施例229。
“降低了敏感性”描述了与常规以较低的MICs(最小抑制浓度)控制的细菌相比需要升高MIC浓度才有效的细菌现象。MIC通过标准体外试验方法(Methods for Dilution Antimicrobial susceptibility Testsfor Bacteria That Grow Aerobically-第四版，Approved Standard，M7-A4，由National Committee for Clinical Laboratory Standard于1997年发表)测定。“降低的敏感性”由NCCLS定义为：对万古霉素来说为8mg/L或以上的MIC，对游壁菌素来说为16mg/L或以上的MIC。
术语“降低的糖肽敏感性”包括完全抗性，NCCLS规定为32mg/L或以上的(对万古霉素或游壁菌素)的MIC。本发明方法针对的菌株的一个例子是Hiramatsu等人在1997年的J.of AntimicrobialChemotherapy，40，135-146页中公开的金黄色葡萄球菌。这种命名为“Mu50”的菌株被认为具有8mg/L的万古霉素的MIC。
术语“降低的糖肽敏感性”意指降低的对万古霉素或游壁菌素的敏感性或降低的对两种抗菌药物敏感性的菌株。所述术语也包括同时降低的对非糖肽抗菌药物诸如青霉素型抗菌药物敏感性菌株。在一优选的实施方案中，本发明涉及不仅降低了对所述糖肽的敏感性而且也抗甲氧苯青霉素(“MRSA”)的金黄色葡萄球菌的控制。上面提及的Hiramatsu菌株是一个例子。
产生降低的敏感性包括抗性的细菌机制有许多。本发明具体涉及所降低的糖肽抗性是由于Van A基因和/或Van B基因以外的因素造成的菌株，即所谓的“Van A和Van B阴性菌株”。
本发明是抗菌治疗常规方式的实践。将目标化合物或其盐给于宿主动物。所述化合物有时可单次成功地给药，但更常见是以数天的时间间隔给药以确保控制。
给药可通过经口途径或通过非肠道途径进行；一般优选静脉输注的给药途径。
使用的准确剂量并不关键，一般随宿主、具体菌株和临床医生所知的其它因素不同而不同。所述剂量必须足够高以确保所述化合物在宿主组织中有足够浓度。一般来说，在本发明中约1-25mg/kg的剂量是有效的；优选的剂量为约1.5-5mg/kg/天。一般成人的日剂量为约100-500mg。
在常规的制药实践中，在本发明中使用的所述化合物优选与一种或多种助剂、载体和/或稀释剂配制。适用的这些成分为本领域技术人员所熟悉，因为是混合这些成分的方法。对于经口给药来说，目标化合物可配制成胶囊、片剂、悬浮液或口服给药的其它形式。对静脉输注来说，所述化合物可溶解于适合的静脉注射液如生理盐水、5％葡萄糖溶液等。
Claims (4)
1.一种治疗金黄色葡萄球菌菌株引起的温血动物的传染病的方法，所述金黄色葡萄球菌(1)具有降低的糖肽敏感性和(2)为Van A和Van B阴性，该方法包括将有效量的NDISACC-(4-(4-氯苯基)苄基)A82846B或其盐给于所述动物。
2.权利要求1的方法，其中所述金黄色葡萄球菌菌株还对甲氧苯青霉素有抗性。
3.权利要求1或2的方法，其中所述金黄色葡萄球菌的菌株具有糖肽抗性。
4.权利要求1或2的方法，其中所述金黄色葡萄球菌菌株为Mu50。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5671297P | 1997-08-22 | 1997-08-22 | |
| US60/056,712 | 1997-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1276728A true CN1276728A (zh) | 2000-12-13 |
Family
ID=22006150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98810295A Pending CN1276728A (zh) | 1997-08-22 | 1998-08-18 | 对金黄色葡萄球菌的治疗 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5994297A (zh) |
| EP (1) | EP0897725B1 (zh) |
| JP (1) | JP2001513573A (zh) |
| KR (1) | KR100589548B1 (zh) |
| CN (1) | CN1276728A (zh) |
| AT (1) | ATE278413T1 (zh) |
| AU (1) | AU747418B2 (zh) |
| BR (1) | BR9811917A (zh) |
| CA (1) | CA2301589A1 (zh) |
| CZ (1) | CZ299098B6 (zh) |
| DE (1) | DE69826795T2 (zh) |
| DK (1) | DK0897725T3 (zh) |
| EA (1) | EA002602B1 (zh) |
| ES (1) | ES2229454T3 (zh) |
| HU (1) | HU226593B1 (zh) |
| ID (1) | ID24908A (zh) |
| IL (2) | IL134597A0 (zh) |
| NO (1) | NO327042B1 (zh) |
| NZ (1) | NZ502762A (zh) |
| PT (1) | PT897725E (zh) |
| TR (1) | TR200000475T2 (zh) |
| UA (1) | UA59410C2 (zh) |
| WO (1) | WO1999010006A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101928331A (zh) * | 2009-06-26 | 2010-12-29 | 上海来益生物药物研究开发中心有限责任公司 | 一种新的化合物及其应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011002249A (es) * | 2008-08-30 | 2011-06-24 | Targanta Therapeutics Corp | Metodos de tratamiento utilizando dosis unicas de oritavancina. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145609C1 (ru) * | 1994-01-28 | 2000-02-20 | Эли Лилли Энд Компани | Производные гликопептида или их соли, способ получения, фармацевтическая композиция |
-
1998
- 1998-07-15 US US09/116,025 patent/US5994297A/en not_active Expired - Fee Related
- 1998-08-18 UA UA2000021041A patent/UA59410C2/uk unknown
- 1998-08-18 ES ES98306571T patent/ES2229454T3/es not_active Expired - Lifetime
- 1998-08-18 AU AU89137/98A patent/AU747418B2/en not_active Ceased
- 1998-08-18 PT PT98306571T patent/PT897725E/pt unknown
- 1998-08-18 DE DE69826795T patent/DE69826795T2/de not_active Expired - Fee Related
- 1998-08-18 EP EP98306571A patent/EP0897725B1/en not_active Expired - Lifetime
- 1998-08-18 DK DK98306571T patent/DK0897725T3/da active
- 1998-08-18 CA CA002301589A patent/CA2301589A1/en not_active Abandoned
- 1998-08-18 TR TR2000/00475T patent/TR200000475T2/xx unknown
- 1998-08-18 CN CN98810295A patent/CN1276728A/zh active Pending
- 1998-08-18 NZ NZ502762A patent/NZ502762A/en unknown
- 1998-08-18 CZ CZ20000619A patent/CZ299098B6/cs not_active IP Right Cessation
- 1998-08-18 BR BR9811917-6A patent/BR9811917A/pt not_active Application Discontinuation
- 1998-08-18 WO PCT/US1998/017138 patent/WO1999010006A1/en active IP Right Grant
- 1998-08-18 IL IL13459798A patent/IL134597A0/xx active IP Right Grant
- 1998-08-18 HU HU0002920A patent/HU226593B1/hu not_active IP Right Cessation
- 1998-08-18 AT AT98306571T patent/ATE278413T1/de not_active IP Right Cessation
- 1998-08-18 KR KR1020007001730A patent/KR100589548B1/ko not_active IP Right Cessation
- 1998-08-18 ID IDW20000332A patent/ID24908A/id unknown
- 1998-08-18 EA EA200000250A patent/EA002602B1/ru not_active IP Right Cessation
- 1998-08-18 JP JP2000507395A patent/JP2001513573A/ja active Pending
-
2000
- 2000-02-17 IL IL134597A patent/IL134597A/en not_active IP Right Cessation
- 2000-02-21 NO NO20000851A patent/NO327042B1/no not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101928331A (zh) * | 2009-06-26 | 2010-12-29 | 上海来益生物药物研究开发中心有限责任公司 | 一种新的化合物及其应用 |
| CN101928331B (zh) * | 2009-06-26 | 2014-05-28 | 上海来益生物药物研究开发中心有限责任公司 | 一种化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE278413T1 (de) | 2004-10-15 |
| ES2229454T3 (es) | 2005-04-16 |
| NZ502762A (en) | 2001-10-26 |
| TR200000475T2 (tr) | 2000-08-21 |
| JP2001513573A (ja) | 2001-09-04 |
| UA59410C2 (uk) | 2003-09-15 |
| AU8913798A (en) | 1999-03-16 |
| DE69826795D1 (de) | 2004-11-11 |
| NO20000851L (no) | 2000-02-21 |
| PT897725E (pt) | 2004-12-31 |
| DK0897725T3 (da) | 2004-12-13 |
| HUP0002920A3 (en) | 2001-12-28 |
| CZ2000619A3 (en) | 2001-05-16 |
| AU747418B2 (en) | 2002-05-16 |
| IL134597A0 (en) | 2001-04-30 |
| HUP0002920A2 (hu) | 2001-01-29 |
| EA200000250A1 (ru) | 2000-08-28 |
| HU226593B1 (en) | 2009-04-28 |
| EP0897725B1 (en) | 2004-10-06 |
| US5994297A (en) | 1999-11-30 |
| NO327042B1 (no) | 2009-04-06 |
| WO1999010006A1 (en) | 1999-03-04 |
| KR20010023108A (ko) | 2001-03-26 |
| EP0897725A3 (en) | 2000-02-09 |
| NO20000851D0 (no) | 2000-02-21 |
| EP0897725A2 (en) | 1999-02-24 |
| KR100589548B1 (ko) | 2006-06-15 |
| CA2301589A1 (en) | 1999-03-04 |
| ID24908A (id) | 2000-08-31 |
| IL134597A (en) | 2007-09-20 |
| BR9811917A (pt) | 2000-08-15 |
| DE69826795T2 (de) | 2005-10-06 |
| CZ299098B6 (cs) | 2008-04-23 |
| EA002602B1 (ru) | 2002-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102227411B (zh) | 抗菌化合物 | |
| EA016803B1 (ru) | Лечение инфекционных заболеваний | |
| US11129811B2 (en) | Methods and compositions to prevent or treat bacterial infections | |
| JPH09132532A (ja) | 抗生物質の抗菌力増強方法 | |
| CN1276728A (zh) | 对金黄色葡萄球菌的治疗 | |
| US20160339057A1 (en) | Novel composition method of using the same for the treatment of lyme disease | |
| EP3762376B1 (en) | Diphenyl substituted thiophene-2-amide derivatives and pharmaceutical compositions thereof useful as antimicrobial | |
| CN102459245B (zh) | 用于治疗感染性疾病的噻吨衍生物 | |
| Pattman et al. | Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole | |
| CN1422279A (zh) | A82846糖肽类似物的选择性n－酰化 | |
| MXPA00001841A (en) | Therapy for staphylococcus aureus | |
| WO1999004816A1 (en) | Proton pump inhibitor in therapeutic combination with antibacterial substances | |
| US20130129695A1 (en) | Methods for treating or inhibiting infection by clostridium difficile | |
| WO2023035950A1 (zh) | 视网膜变性的治疗方法 | |
| EP1312364A1 (en) | Cytokine production inhibitors | |
| CN106673989A (zh) | 一种药物组合物及其制备方法和应用 | |
| Sander et al. | The treatment of urinary tract infections in out-patients. A double-blind comparison between trimethoprim and nitrofurantoin | |
| Koeth et al. | 714. Analysis of the Effect of Urine on the In Vitro Activity of Gepotidacin and Levofloxacin Against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus saprophyticus | |
| DE202017107259U1 (de) | Antibakterielle Zusammensetzung umfassend Mikrozin S und Antibiotikum | |
| Midtvedt | Penicillins, cephalosporins and tetracyclines | |
| CN106632286A (zh) | 一种药物组合物及其制备方法和应用 | |
| PL190418B1 (pl) | Zastosowanie NDISACC-(4-(4-chlorofenylo)benzylo)-A82846B lub jego soli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1033272 Country of ref document: HK |